Research Progress in Tumor Angiogenesis and Drug Resistance in Breast Cancer

Overview

Journal Cancer Biol Med

Specialty Oncology

Date 2024 Jun 28

PMID 38940663

Authors

Jiancheng Mou

Chenhong Li

Qinghui Zheng

Xuli Meng

Hongchao Tang

Affiliations

Soon will be listed here.

Abstract

Angiogenesis is considered a hallmark pathophysiological process in tumor development. Aberrant vasculature resulting from tumor angiogenesis plays a critical role in the development of resistance to breast cancer treatments, exacerbation of tumor hypoxia, decreased effective drug concentrations within tumors, and immune-related mechanisms. Antiangiogenic therapy can counteract these breast cancer resistance factors by promoting tumor vascular normalization. The combination of antiangiogenic therapy with chemotherapy, targeted therapy, or immunotherapy has emerged as a promising approach for overcoming drug resistance in breast cancer. This review examines the mechanisms associated with angiogenesis and the interactions among tumor angiogenesis, the hypoxic tumor microenvironment, drug distribution, and immune mechanisms in breast cancer. Furthermore, this review provides a comprehensive summary of specific antiangiogenic drugs, and relevant studies assessing the reversal of drug resistance in breast cancer. The potential mechanisms underlying these interventions are discussed, and prospects for the clinical application of antiangiogenic therapy to overcome breast cancer treatment resistance are highlighted.

Citing Articles

Rack1 promotes breast cancer stemness properties and tumorigenesis through the E2F1-SOX2 axis.

Jia Y, Zhang L, Zhou W, Chen S, Zhang H, Liu L Cancer Cell Int. 2025; 25(1):40.

PMID: 39939870 PMC: 11823217. DOI: 10.1186/s12935-025-03678-1.

Oxyresveratrol as a novel ferroptosis inducer exhibits anticancer activity against breast cancer via the EGFR/PI3K/AKT/GPX4 signalling axis.

Xiang L, Li Q, Guan Z, Wang G, Yu X, Zhang X Front Pharmacol. 2025; 15:1527286.

PMID: 39881871 PMC: 11775479. DOI: 10.3389/fphar.2024.1527286.

The potential of lenvatinib in breast cancer therapy.

Shang Y, Liu T, Wang W Med Oncol. 2024; 41(9):233.

PMID: 39172293 DOI: 10.1007/s12032-024-02477-4.

References

Kerbel R . Reappraising antiangiogenic therapy for breast cancer. Breast. 2011; 20 Suppl 3:S56-60. PMC: 4540338. DOI: 10.1016/S0960-9776(11)70295-8. View

Yamazaki C, Yamaguchi A, Anami Y, Xiong W, Otani Y, Lee J . Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun. 2021; 12(1):3528. PMC: 8192907. DOI: 10.1038/s41467-021-23793-7. View

Muoio M, Talia M, Lappano R, Sims A, Vella V, Cirillo F . Activation of the S100A7/RAGE Pathway by IGF-1 Contributes to Angiogenesis in Breast Cancer. Cancers (Basel). 2021; 13(4). PMC: 7915817. DOI: 10.3390/cancers13040621. View

Wang D, Wang Y, Wu X, Kong X, Li J, Dong C . RNF20 Is Critical for Snail-Mediated E-Cadherin Repression in Human Breast Cancer. Front Oncol. 2020; 10:613470. PMC: 7753216. DOI: 10.3389/fonc.2020.613470. View

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

Jiang W, Chen L, Guo X, Cheng C, Luo Y, Wang J . Combating multidrug resistance and metastasis of breast cancer by endoplasmic reticulum stress and cell-nucleus penetration enhanced immunochemotherapy. Theranostics. 2022; 12(6):2987-3006. PMC: 8965496. DOI: 10.7150/thno.71693. View

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

Sun R, Luo H, Su J, Di S, Zhou M, Shi B . Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice. Mol Ther. 2020; 29(1):60-74. PMC: 7791086. DOI: 10.1016/j.ymthe.2020.09.034. View

10.

Nakuluri K, Mukhi D, Nishad R, Saleem M, Mungamuri S, Menon R . Hypoxia induces ZEB2 in podocytes: Implications in the pathogenesis of proteinuria. J Cell Physiol. 2018; 234(5):6503-6518. DOI: 10.1002/jcp.27387. View

11.

Tang L, Xiong W, Zhang L, Wang D, Wang Y, Wu Y . circSETD3 regulates MAPRE1 through miR-615-5p and miR-1538 sponges to promote migration and invasion in nasopharyngeal carcinoma. Oncogene. 2020; 40(2):307-321. DOI: 10.1038/s41388-020-01531-5. View

12.

Ba X, Huang Y, Shen P, Huang Y, Wang H, Han L . WTD Attenuating Rheumatoid Arthritis Suppressing Angiogenesis and Modulating the PI3K/AKT/mTOR/HIF-1α Pathway. Front Pharmacol. 2021; 12:696802. PMC: 8502817. DOI: 10.3389/fphar.2021.696802. View

13.

Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P . Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol. 2004; 165(1):35-52. PMC: 1618540. DOI: 10.1016/S0002-9440(10)63273-7. View

14.

Bai R, Li Y, Jian L, Yang Y, Zhao L, Wei M . The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies. Mol Cancer. 2022; 21(1):177. PMC: 9454207. DOI: 10.1186/s12943-022-01645-2. View

15.

Huang Y, Yuan J, Righi E, Kamoun W, Ancukiewicz M, Nezivar J . Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012; 109(43):17561-6. PMC: 3491458. DOI: 10.1073/pnas.1215397109. View

16.

Lu H, Chen I, Shimoda L, Park Y, Zhang C, Tran L . Chemotherapy-Induced Ca Release Stimulates Breast Cancer Stem Cell Enrichment. Cell Rep. 2021; 34(1):108605. DOI: 10.1016/j.celrep.2020.108605. View

17.

Vetsika E, Koukos A, Kotsakis A . Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer. Cells. 2019; 8(12). PMC: 6953061. DOI: 10.3390/cells8121647. View

18.

Doublier S, Belisario D, Polimeni M, Annaratone L, Riganti C, Allia E . HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer. 2012; 12:4. PMC: 3262753. DOI: 10.1186/1471-2407-12-4. View

19.

Yang Z, Sun B, Li Y, Zhao X, Zhao X, Gu Q . ZEB2 promotes vasculogenic mimicry by TGF-β1 induced epithelial-to-mesenchymal transition in hepatocellular carcinoma. Exp Mol Pathol. 2015; 98(3):352-9. DOI: 10.1016/j.yexmp.2015.03.030. View

20.

Allen E, Jabouille A, Rivera L, Lodewijckx I, Missiaen R, Steri V . Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017; 9(385). PMC: 5554432. DOI: 10.1126/scitranslmed.aak9679. View